Top.Mail.Ru

Псевдопрогрессирование на фоне иммунотерапии


Информация только для специалистов в сфере медицины, фармации и здравоохранения!

 48216

Псевдопрогрессирование на фоне иммунотерапии

Журнал "Медицинский совет" №10, 2019

DOI: https://doi.org/10.21518/2079-701X-2019-10-10-14

Юдин Д.И., к.м.н., старший научный сотрудник, Лактионов К.К., д.м.н., заместитель директора, Саранцева К.А., к.м.н., врачонколог, Бредер В.В., д.м.н., ведущий научный сотрудник, Реутова Е.В., к.м.н., старший научный сотрудник, Борисова О.И., врач-онколог, Ардзинба М.С., к.м.н., врачонколог, Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации

В настоящий момент растет число пациентов, получающих иммунотерапию ингибиторами контрольных точек. Вместе с этим все чаще клиницисты встречают такой клинический феномен, как псевдопрогрессирование. Рентгенологические признаки псевдопрогрессирования отсутствуют. Каждый такой случай требует индивидуального решения.

Pseudoprogression in patients on immunotherapy

Yudin Denis Ivanovich, Cand. of Sci. (Med), Senior Researcher, Laktionov Konstantin Konstantinovich, Dr. of Sci. (Med), Sarantseva Ksenia Andreevna, Cand. of Sci. (Med), oncologist, Breder Valery Vladimirovich, Dr. of Sci. (Med), Leading Researcher, Reutova Elena Valeryevna, Cand. of Sci. (Med), Borisova Olga Igorevna, Oncologist, Ardzinba Merab Sergeyevich, Cand. of Sci. (Med), Oncologist, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation

Now the number of patients receiving immunotherapy with checkpoint inhibitors is growing. At the same time, clinicians increasingly encounter such a clinical phenomenon as pseudoprogression. Nowadays we have no radiological evidences of pseudoprogression. The every such case requires an individual decision.

Загрузить файл в формате PDF


Литература / References

  1. Chiou V.L., Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol. 2015 Nov 1;33(31):3541-3.
  2. Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009 Januar;45(2):228-47.
  3. Wolchok J.D., Hoos A., Bohnsack O. et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-related Response Criteria. Clin Cancer Res. 2009;15(23) December 1, 2009.
  4. Nishino M., Gargano M., Suda M., Ramaiya N.H., Hodi F.S. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immuno ther Cancer. 2014; 2: 17. https://doi.org/10.1186/2051-1426-2-17.
  5. Nishino M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15;19(14):3936-43.
  6. Nishino M., Ramaiya N.H., Chambers E.S. et al. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer. 2016;4:84.
  7. Seymour L., Bogaerts J., Perrone A. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143-52.
  8. Hodi F., Ballinger M., Lyons B. et al. Immune- Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018;36:850-858.
  9. Brahmer J.R., Tykodi S.S., Chow L.Q. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465
  10. Topalian S.L., Hodi F.S., Brahmer J.R. et al. Safety, activity, and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
  11. Topalian S.L., Sznol M., McDermott D.F. et al. Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020-1030.
  12. Wolchok J.D., Kluger H., Callahan M.K. et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-133.
  13. 14. Hodi F.S., Ribas A., Daud A. et al. Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014;(suppl 15s):32. abstr 3006.
  14. Wolchok J.D., Hamid O., Ribas A. Atypical patterns of response in patients (pts) with metastatic melanoma treated withpembrolizumab (MK-3475) in KEYNOTE-001. J Clin Oncol. 2015;33(15 supplement):3000. https://doi.org/10.1200/jco.2015.33.15_suppl.3000.
  15. Nishino M., Dahlberg S., Adeni A. et al. Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res. 2017 October 1;23(19). https://doi.org/10.1158/1078-0432.CCR-17-1434.
  16. Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A. et al. Overall survival and long-term safety of nivolumab (Anti- Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33: 2004-12.
  17. Grierson P., Crites D., Ruzinova M. et al. Distinct Clinical and Magnetic Resonance Features of Metastatic Hepatocellular Carcinoma Treated With Pembrolizumab: A Case Report of Late Response After Pseudoprogression. Hepatology Communications. 2018;2:148-151.
  18. Sweis R., Zha Y. et al. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. Journal for ImmunoTherapy of Cancer. 2018;6:24. https://doi.org/10.1186/s40425-018-0334-x.
  19. Kolla B.C., Patel M.R. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy - a report of two cases. J Immunother Cancer. 2016;4:80.




Последние статьи